Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
Cristina MuniesaFernando GallardoIgnacio García DovalM Teresa EstrachAndrea CombaliaMercedes Morillo-AndújarFátima De la Cruz-VicenteSalma MachanCristina Moya-MartínezRoger RoviraBlanca Sanchez-GonzalezElvira AceboElena AmutioYeray PeñateMaria Del Carmen Losada-CastilloM Pilar García-MuretHelena IznardoConcepción Román-CurtoJavier CañuetoRicardo Fernández-de-MisaÁngeles FlórezRosa María IzuIgnacio Torres-NavarroAna ZayasGema Pérez-ParedesMar BlanesJ Ignacio YanguasAmparo Pérez-FerriolsMarta Callejas-CharaviaPablo Luis Ortiz-RomeroAmalia Pérez-GilLucia Prieto-TorresEva González-BarcaOctavio ServitjePublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases.